Supernus gets regulatory clearance for Sage acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 28, 2025 8:25 AM EDTROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025.
On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the "Merger... More
